Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00635765 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: C2L-OCT-01 PR 30 mg

Sponsor

Ambrilia Biopharma, Inc.